Neurological Manifestations of Arsenic Intoxication Clinical Presentation

  • Author: Frances M Dyro, MD; Chief Editor: Tarakad S Ramachandran, MBBS, FRCP(C), FACP   more...
 
Updated: May 17, 2012
 

History

Acute toxicity following ingestion, inhalation, or absorption of inorganic arsenic produces a burning sensation in the mouth and throat. This is followed, usually somewhat later, by severe gastrointestinal distress with copious and severe diarrhea and vomiting. Vertigo, delirium, coma, and often convulsions are seen as the toxicity is manifest. Circulatory collapse and renal and hepatic failure ensue, and hemolysis usually occurs 4-6 hours after onset of evidence of toxicity. Acute symptoms typically develop hours after exposure to inorganic arsenic. Inhalation of arsine gas produces headache, malaise, weakness, dizziness, dyspnea, and GI distress more rapidly.

The typical picture in subacute arsenic toxicity includes the onset of gastrointestinal symptoms—nausea, vomiting, and diarrhea—which may be intermittent but in retrospect are associated with ingestion of hot or cold beverages. For a layperson's account of an experience with arsenic poisoning, read "My Husband Poisoned Me" by Ellen Harris in the March 2000 issue of McCall's Magazine, pages 68-73.

Chronic exposure effects should be suspected when a patient presents with a distal sensorimotor neuropathy accompanied by skin hyperpigmentation. History of drinking well water is an additional clue. Bae et al have written on the role of a rice cooking technique associated with arsenic toxicity in Bangladesh.[3]

Next

Physical

Heavy metal poisonings have many similarities, making clinical distinctions between them difficult at times. Arsenic is more likely than other heavy metals to produce a dramatic gastroenteric picture when ingested. Inhalation of arsine gas produces clinical features whose onset is dependent on the degree of exposure. The initial complaints may be vague, with headache, malaise, weakness, dizziness, and dyspnea. Later, the features are the same as those seen in inorganic arsenic ingestion. The cutaneous manifestations are rather different depending on the heavy metal exposure.

  • Cutaneous: Hyperpigmentation of the skin of the face or extremities is in a "raindrop" distribution. The skin has a peculiar bronze tint. A patient described by Kyle and Pease had pigmentation of the buccal mucosa resembling the hyperpigmentation of Addison disease.[17] Oral herpetiform lesions or a diffuse macular rash may be present, as may brawny, nonpruritic desquamation and patchy alopecia as well as hyperkeratosis of the palms and soles. Mees lines are transverse, 1-2 mm white striations in the fingernails, which may be deformed or fall out within 2-3 weeks of exposure. The Mees lines are actual arsenic deposits. Because of the availability of sulfhydryl groups in keratin, arsenic can be measured in hair and fingernail samples. Arsenic can be detected in hair samples as early as 30 hours after ingestion and as late as 9 years after ingestion. Thallium toxicity can be suspected in case of hair loss and fingernail loss, but thallium is more likely to produce hyperglycemia.
  • Neurological: Paresthesias and numbness, usually in a symmetric stocking-glove distribution, and muscle weakness are a result of peripheral neuropathy. The onset and progression may be mistaken for Guillain-Barré syndrome.[11] This problem may persist long after arsenic exposure stops. Fatigue and weakness are major complaints. The neuropathy is not seen acutely but develops over the weeks subsequent to exposure in acute or subacute toxicity. In regular, long-term arsenic exposure, the presenting complaint is frequently a sensory neuropathy with features that resemble an alcoholic neuropathy.[18] Burning paresthesias in glove and stocking distribution, early loss of stretch reflexes, and later weakness are seen. In severe toxicity, flaccid paralysis may appear in the lower extremities, then the upper extremities. This is maximal about 4 weeks after acute exposure. Again, the clinical picture resembles Guillain-Barré syndrome.
  • Hematologic: Anemia with leukopenia is seen frequently; splenomegaly may be apparent. Granulocytopenia and an increase in the eosinophil count often occur.
  • Systemic complaints of regional subcutaneous edema are present in arsenic intoxication. The eyelids in particular, and legs less frequently, become quite edematous.
Previous
 
 
Contributor Information and Disclosures
Author

Frances M Dyro, MD  Associate Professor of Neurology, New York Medical College; Neuromuscular Section, Department of Neurology, Westchester Medical Center

Frances M Dyro, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Muscular Dystrophy Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Jonathan S Rutchik, MD, MPH  Clinical Professor, Division of Occupational Medicine, Department of Neurology, Environmental and Occupational Medicine, University of California, San Francisco, School of Medicine

Jonathan S Rutchik, MD, MPH is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Occupational and Environmental Medicine, and Society of Toxicology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Glenn Lopate, MD  Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Baxter Grant/research funds Other; Amgen Grant/research funds None

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

Tarakad S Ramachandran, MBBS, FRCP(C), FACP  Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, FRCP(C), FACP is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners, American College of International Physicians, American College of Managed Care Medicine, American College of Physicians, American Heart Association, American Stroke Association, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, and Royal Society of Medicine

Disclosure: Abbott Labs None None; Teva Marion None None; Boeringer-Ingelheim Honoraria Speaking and teaching

References
  1. Ford M. Arsenic. In: Goldfrank LR, Flomenbaum NE, et al, eds. Toxicologic Emergencies. 1994:1011-1029.

  2. Axelson O, Dahlgren E, Jansson CD, Rehnlund SO. Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br J Ind Med. Feb 1978;35(1):8-15. [Medline].

  3. Bae M, Watanabe C, Inaoka T, et al. Arsenic in cooked rice in Bangladesh. Lancet. Dec 7 2002;360(9348):1839-40. [Medline].

  4. Franzblau A, Lilis R. Acute arsenic intoxication from environmental arsenic exposure. Arch Environ Health. Nov-Dec 1989;44(6):385-90. [Medline].

  5. Heinrich-Ramm R, Mindt-Prufert S, Szadkowski D. Arsenic species excretion in a group of persons in northern Germany-- contribution to the evaluation of reference values. Int J Hyg Environ Health. Jul 2001;203(5-6):475-7. [Medline].

  6. Ball P. Arsenic-free water still a pipedream. Nature. Jul 21 2005;436(7049):313. [Medline].

  7. Fowler BA, Weissberg JB. Arsine poisoning. N Engl J Med. Nov 28 1974;291(22):1171-4. [Medline].

  8. Heyman A, Pfeiffer JB, Willett RW, Taylor HM. Peripheral neuropathy caused by arsenical intoxication; a study of 41 cases with observations on the effects of BAL (2, 3, dimercapto-propanol). N Engl J Med. Mar 1 1956;254(9):401-9. [Medline].

  9. Chen CJ, Wu MM, Lee SS, et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. Sep-Oct 1988;8(5):452-60. [Medline].

  10. Watanabe C, Kawata A, Sudo N, et al. Water intake in an Asian population living in arsenic-contaminated area. Toxicol Appl Pharmacol. Aug 1 2004;198(3):272-82. [Medline].

  11. Donofrio PD, Wilbourn AJ, Albers JW, et al. Acute arsenic intoxication presenting as Guillain-Barre-like syndrome. Muscle Nerve. Feb 1987;10(2):114-20. [Medline].

  12. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. Mar 1 1992;135(5):462-76. [Medline].

  13. Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A reanalysis. Am J Epidemiol. Jun 1987;125(6):929-38. [Medline].

  14. Karagas MR, Le CX, Morris S, et al. Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health. 2001;14(2):171-5. [Medline].

  15. Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet. Jul 24 2010;376(9737):252-8. [Medline].

  16. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. Dec 16 2006;368(9553):2167-78. [Medline].

  17. Kyle RA, Pease GL. Hematologic aspects of arsenic intoxication. N Engl J Med. Jul 1 1965;273:18-23. [Medline].

  18. Massey EW. Arsenic neuropathy. Neurology. Aug 1981;31(8):1057-8. [Medline].

  19. Moyer TP. Testing for arsenic. Mayo Clin Proc. Dec 1993;68(12):1210-1. [Medline].

  20. Lee AM, Fraumeni JF Jr. Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst. Jun 1969;42(6):1045-52. [Medline].

  21. Neubauer O. Arsenical cancer. Br J Cancer. 1947;1:192-251.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.